

Note to readers with disabilities: *EHP* strives to ensure that all journal content is accessible to all readers. However, some figures and Supplemental Material published in *EHP* articles may not conform to [508 standards](#) due to the complexity of the information being presented. If you need assistance accessing journal content, please contact ehp508@niehs.nih.gov. Our staff will work with you to assess and meet your accessibility needs within 3 working days.

Supplemental Material

Association of Arsenic Exposure with Whole Blood DNA Methylation: An Epigenome-Wide Study of Bangladeshi Adults

Kathryn Demanelis, Maria Argos, Lin Tong, Justin Shinkle, Mekala Sabarinathan, Muhammad Rakibuz-Zaman, Golam Sarwar, Hasan Shahriar, Tariqul Islam, Mahfuzar Rahman, Mohammad Yunus, Joseph H. Graziano, Karin Broberg, Karin Engström, Farzana Jasmine, Habibul Ahsan, and Brandon L. Pierce

Table of Contents

Figure S1. QQ-plot of epigenome-wide analysis results of log₂-transformed urinary arsenic concentration (creatinine-adjusted) in HEALS (n=396).

Figure S2. Urinary arsenic concentration (creatinine-adjusted) and DNA methylation at arsenic-associated CpGs (FDR < 0.05) in HEALS and reported Pearson correlations.

Figure S3. Relationship between water and urinary arsenic measurements in HEALS (n=396).

Figure S4. QQ-plot of the observed p-values from epigenome-wide analysis of log₂-transformed water arsenic concentration in HEALS (n=396).

Figure S5. Genome-wide associations between log₂-transformed water arsenic concentration and CpG site-specific methylation in HEALS (n=396).

Figure S6. QQ-plot of epigenome-wide analysis results for log₂-transformed urinary arsenic concentration (creatinine-adjusted) in BEST (n=400).

Figure S7. Genome-wide associations between log₂-transformed urinary arsenic concentration (creatinine-adjusted) and CpG site-specific methylation in BEST (n=400).

Figure S8. Enrichment of urinary arsenic-associated CpGs identified in meta-analysis of HEALS (n=396) and BEST (n=400) within genomic features stratified by direction of association (FDR < 0.05).

Table S1. Results from different epigenome-wide analysis methods and exposure modeling in HEALS (n=396).

Table S2. Association between estimated cell type proportions and log₂-transformed urinary arsenic concentration (creatinine-adjusted) in HEALS (n=396).

Table S3. Regions of methylation associated with log₂-transformed urinary arsenic concentration in HEALS (minimum FDR < 10⁻⁴).

Table S4. Results from gene set enrichment analysis based on KEGG pathways for genes annotating to urinary arsenic-associated CpGs from HEALS discovery analysis and meta-analysis of HEALS and BEST.

Table S5. CpGs associated with log₂-transformed urinary arsenic from meta-analysis ($p < 1.3 \times 10^{-7}$) and their relationship with gene expression in BEST (n=371).

Table S6. Summary of cis-mQTLs results from HEALS (n=389) for CpGs identified in meta-analysis.

Table S7. Summary of disease and trait associations with genetic variants within or near genes annotated to urinary arsenic-associated CpGs from the GWAS Catalog.

Additional File- Excel Document

References